Neuroene will be presenting in the Company Showcase at the Blue Knight Symposium! Come and hear us pitch in Boston on Sunday, June 4th at 4:45pm. Click here to learn more about our lead candidate and pipeline. About the 2023 Symposium Join us for a global conversation with innovators, investors, partners and thought leaders to […]
Neuroene Therapeutics has been chosen as a Startup Stadium Finalist at the BIO International Convention! Come and hear us pitch in Boston on Wednesday, June 7th at 11am. Click here to learn more about our lead candidate and pipeline. About Start-Up Stadium Start-Up Stadium is designed to provide start-up companies with the opportunity to engage […]
Neuroene Therapeutics has been awarded a Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The award supports Neuroene’s ongoing research and development of a novel class of well-tolerated compounds protects and ameliorates mitochondrial and neurological diseases. Neuroene’s lead antiseizure drug (ASD) candidate has demonstrated broad-spectrum antiseizure activity in several animal […]
Neuroene Therapeutics is now a resident company of Johnson & Johnson Innovation (JLABS), a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS […]